HIGHLIGHTS
- who: GI cancer and collaborators from the Biosciences Institute, Faculty of University, Newcastle upon Tyne, intervention with anti-u00ad, and/or a , inhibitor was have published the research: CXCR2 inhibition enables NASH-HCC immunotherapy, in the Journal: (JOURNAL) of 17/03/2022
- what: The authors propose that combined neutrophil phenotype modification and ICI may achieve improved outcomes in NASH-u00adHCC. Although CXCR2 antagonism alone delivered modest model-u00addependant antitumour benefit, similar to observations made in models of non-u00adhepatic cancers the authors show that CXCR2 inhibition sensitises to anti-u00adPD1 immunotherapy in Leslie J, et_al . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.